Intellia Therapeutics Inc (NTLA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Intellia Therapeutics Inc (NTLA) has a cash flow conversion efficiency ratio of -0.103x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-69.28 Million) by net assets ($671.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Intellia Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Intellia Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Intellia Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Intellia Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Intellia Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Rayitek Hi-Tech Film Co. Ltd. A
SHG:688323
|
0.017x |
|
Kepco Plant S&
KO:051600
|
0.008x |
|
HuBei SanFeng Intelligent Conveying Equipment Co Ltd
SHE:300276
|
0.100x |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
0.016x |
|
Koh Young Technology Inc
KQ:098460
|
0.000x |
|
Bank First National Corp
NASDAQ:BFC
|
-0.014x |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
0.056x |
|
Apex Dynamics Inc.
TW:4583
|
0.035x |
Annual Cash Flow Conversion Efficiency for Intellia Therapeutics Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Intellia Therapeutics Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Intellia Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $671.39 Million | $-348.88 Million | -0.520x | -29.87% |
| 2024-12-31 | $871.96 Million | $-348.88 Million | -0.400x | -6.62% |
| 2023-12-31 | $1.05 Billion | $-394.09 Million | -0.375x | -39.12% |
| 2022-12-31 | $1.24 Billion | $-333.29 Million | -0.270x | -24.69% |
| 2021-12-31 | $1.04 Billion | $-225.03 Million | -0.216x | -128.44% |
| 2020-12-31 | $527.07 Million | $-49.91 Million | -0.095x | +75.25% |
| 2019-12-31 | $269.88 Million | $-103.24 Million | -0.383x | -73.56% |
| 2018-12-31 | $277.92 Million | $-61.26 Million | -0.220x | -1.50% |
| 2017-12-31 | $300.60 Million | $-65.28 Million | -0.217x | -226.19% |
| 2016-12-31 | $209.84 Million | $36.11 Million | 0.172x | +757.44% |
| 2015-12-31 | $67.36 Million | $-1.76 Million | -0.026x | +94.31% |
| 2014-12-31 | $7.57 Million | $-3.48 Million | -0.460x | -- |
About Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agree… Read more